Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV000993610 | SCV001146716 | likely pathogenic | Phenylketonuria | 2019-08-26 | reviewed by expert panel | curation | The c.169_171del in-frame deletion variant has been identified in at least 2 probands with phenotypes of mild to classic PKU (PMIDs: 18299955, 22106832). It has been detected in trans with pathogenic variants Ala403Val (PMID: 18299955) and c.1066-11G>A (PMID: 22106832). This variant is absent from 1000G, ESP, and gnomAD databases. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PM3_Strong, PM2, PM4, PP4. |
Labcorp Genetics |
RCV000993610 | SCV002228241 | pathogenic | Phenylketonuria | 2022-01-18 | criteria provided, single submitter | clinical testing | This variant has been observed in individual(s) with hyperphenylalaninemia (PMID: 18299955, 22106832, 32668217, 32905092). This variant, c.169_171del, results in the deletion of 1 amino acid(s) of the PAH protein (p.Glu57del), but otherwise preserves the integrity of the reading frame. This variant is not present in population databases (gnomAD no frequency). This variant is also known as IVS2 -2 del. ClinVar contains an entry for this variant (Variation ID: 102613). This variant disrupts a region of the PAH protein in which other variant(s) (p.Glu57Lys) have been observed in individuals with PAH-related conditions (PMID: 21147011). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV000993610 | SCV004209711 | pathogenic | Phenylketonuria | 2023-01-18 | criteria provided, single submitter | clinical testing | |
De |
RCV000088855 | SCV000119450 | not provided | not provided | no assertion provided | not provided |